Infinity Pharmaceuticals, Inc. (INFI) |
|
0.64 -0.01 (-1.54%)
|
01-27 16:00 |
|
Open: |
0.65 |
Pre. Close: |
0.65 |
|
High:
|
0.6788 |
Low:
|
0.62 |
|
Volume:
|
447,402 |
Market Cap:
|
57(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:45:30 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.89 One year: 1.05 |
| Support: |
Support1: 0.58 Support2: 0.46 |
| Resistance: |
Resistance1: 0.76 Resistance2: 0.89 |
| Pivot: |
0.66  |
| Moving Average: |
MA(5): 0.64  MA(20): 0.64
MA(100): 0.89 MA(250): 0.91 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 32.6 %D(3): 40.3 |
| RSI: |
RSI(14): 50 |
| 52-week: |
High: 1.75 Low: 0.43 |
| Average Vol(K): |
3-Month: 707 (K) 10-Days: 433 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ INFI ] has closed above bottom band by 29.8%. Bollinger Bands are 59% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.68 - 0.68 |
0.68 - 0.69 |
|
Low:
|
0.61 - 0.61 |
0.61 - 0.62 |
|
Close:
|
0.63 - 0.64 |
0.64 - 0.65 |
|
Company Description |
|
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Sun, 29 Jan 2023
Prismo Metals Announces Definitive Agreement to Acquire Majority Interest in Hot Breccia Property in the Arizona Copper Belt - Yahoo Finance
Sat, 28 Jan 2023
Online streaming platform Enterinfi is enabling more creative stories to come to light that mainstream avenues - EIN News
Sat, 14 Jan 2023
What Does a Risk Analysis Say About Insured Finance (INFI) Saturday? - InvestorsObserver
Wed, 04 Jan 2023
Following 15% Rise Last Week, Infinity Pharmaceuticals Shareholders Still Down 72% Over Past Five Years - Simply Wall St
Mon, 14 Nov 2022
Infinity Pharmaceuticals (INFI) Stock Drops Over 20%: Details - Pulse 2.0
Mon, 14 Nov 2022
Infinity Pharmaceuticals Inc : Losses of 12 cents announced for third quarter - Kalkine Media
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
89 (M) |
|
% Held by Insiders
|
7.684e+007 (%) |
|
% Held by Institutions
|
1.2 (%) |
|
Shares Short
|
985 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.633e+007 |
|
EPS Est Next Qtl
|
-0.21 |
|
EPS Est This Year
|
-0.93 |
|
EPS Est Next Year
|
-1.5 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
871.4 |
|
Return on Equity (ttm)
|
-40.1 |
|
Qtrly Rev. Growth
|
2.5e+006 |
|
Gross Profit (p.s.)
|
53.98 |
|
Sales Per Share
|
-357.7 |
|
EBITDA (p.s.)
|
-2.51301e+007 |
|
Qtrly Earnings Growth
|
-0.6 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-43 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
-6.56 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.02e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
